HS Optimus (SGX:504) booked an attributable profit to owners of SG$4.1 million during the fiscal second half ended March 31, against an attributable loss of SG$815,000 a year earlier, according to a Thursday bourse filing.
Earnings per share came in at SG$0.00075 compared with SG$0.00015 in the year-ago period.
Revenue declined 13% year over year to SG$5.6 million from SG$6.4 million.
Hillgrove Resources (ASX:HGO) completed the AU$5 million stage one consideration payment to Havilah Resources (ASX:HAV) under the farm-in agreement on the Mutooroo project in South Australia, according to a Friday filing with the Australian bourse.The company issued 116.3 million shares as well as 116.3 million unlisted options at an exercise price of AU$0.052, with an expiry date of June 29, 2028, the filing said.The issue of the shares and options was conditional on the renewal of exploration license 6592, which was fulfilled on May 22.Meanwhile, the first phase of the Mutooroo pre‑feasibility study has started, with mobilization of the study team underway, per the filing.Havilah Resources shares rose 2% in midday trade Friday.
Jiangsu Hengrui Pharmaceuticals (SHA:600276) said its Guangdong subsidiary received China's regulatory approval to conduct clinical trials for SHR-1819 Injection,The drug is indicated for treating atopic dermatitis in children aged six months to five years, according to a Thursday filing with the Shanghai bourse.Shares of the pharmaceutical company rose 1% in recent trade.
Deepexi Technology (HKG:1384) completed the placement of 7.94 million new shares at HK$50.58 apiece, raising net proceeds of about HK$395 million, according to a Thursday Hong Kong bourse filing.Shares of the large-model AI application provider were down nearly 5% in Friday morning trading.The placing shares represent about 2.4% of the company's enlarged share capital and were placed to not fewer than six independent investors.Deepexi said the proceeds will be used for overseas market expansion and localization capabilities building, potential strategic investments and acquisitions, and general corporate purposes.